PVR and hepatocellular carcinoma: This finding is consistent with a study on hepatocellular cancer showing anti-PD-1 therapy greatly upregulated TIGIT expression in activated T cells and the CD155/TIGIT axis contributed to anti-PD-1 treatment resistance (30).